NCT01920061 2022-09-13A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)PfizerPhase 1 Completed110 enrolled 80 charts
NCT01420081 2019-01-08A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial CancerPfizerPhase 2 Terminated67 enrolled 37 charts